PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-304.29%
Negative EBIT growth while CRVO is at 207.94%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
27.06%
Positive operating income growth while CRVO is negative. John Neff might view this as a competitive edge in operations.
-304.05%
Negative net income growth while CRVO stands at 194.78%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-302.06%
Negative EPS growth while CRVO is at 119.93%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-288.66%
Negative diluted EPS growth while CRVO is at 119.93%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.11%
Share reduction more than 1.5x CRVO's 343.75%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
3.68%
Diluted share reduction more than 1.5x CRVO's 343.75%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
56.08%
Positive OCF growth while CRVO is negative. John Neff would see this as a clear operational advantage vs. the competitor.
56.11%
Positive FCF growth while CRVO is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-18524.76%
Negative 10Y OCF/share CAGR while CRVO stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-17391.51%
Negative 5Y OCF/share CAGR while CRVO is at 64.70%. Joel Greenblatt would question the firm’s operational model or cost structure.
-1778.39%
Negative 3Y OCF/share CAGR while CRVO stands at 83.15%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-42866.91%
Negative 10Y net income/share CAGR while CRVO is at 0.00%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-15208.07%
Negative 5Y net income/share CAGR while CRVO is 210.90%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-5247.61%
Negative 3Y CAGR while CRVO is 119.43%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
4590.00%
Equity/share CAGR of 4590.00% while CRVO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
1682.71%
Positive 5Y equity/share CAGR while CRVO is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
1405.22%
Positive short-term equity growth while CRVO is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
70.82%
Positive asset growth while CRVO is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
247.25%
BV/share growth above 1.5x CRVO's 90.22%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-50.51%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-53.09%
Our R&D shrinks while CRVO invests at 0.00%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
3.56%
SG&A growth well above CRVO's 4.80%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.